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ABSTRACT 
The Rising Incidence of Small Endocrine Cancers in the United States: Effects on 
Surgical Therapy in an Age of Imaging 
Eric J. Kuo1, Ronald R. Salem1, Sanziana A. Roman2, Julie A. Sosa2, 1Department of 
Surgery, Yale School of Medicine, New Haven, CT, 2Department of Surgery, Duke 
University School of Medicine, Durham, NC 
 
The increasing utilization of imaging technology has led to the diagnosis of cancers earlier in their 
clinical course. When small tumor size is coupled with relatively indolent histology, excellent oncologic 
outcomes require the risks of surgery to be carefully considered. However, characteristics and outcomes of 
small cancers of the thyroid and endocrine pancreas remain poorly defined, and evidence to guide their 
management is sparse. 
Patients with tall cell (mTCV) and diffuse sclerosing (mDSV) variants of papillary thyroid 
microcarcinoma (mPTC), follicular (mFTC) and Hurthle cell microcarcinoma (mHCC), parathyroid 
carcinoma (PC) and pancreatic neuroendocrine tumors (PNETs) ≤ 2 cm in size were selected from the 
National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) database, 1988-2009. 
Data regarding incidence, characteristics, and outcomes were extracted and analyzed with χ2 tests, 
ANOVA, the Kaplan Meier method, log-rank tests, and Cox proportional hazards. 
97 mTCV, 90 mDSV, 371 mFTC, 193 mHCC, and 263 PNETs ≤ 2 cm were identified. The 
incidence of mTCV, mDSV, and mFTC remained stable throughout the study period, while the incidences 
of mHCC and PNETs ≤ 2 cm increased by 400% and 710% over the study period, respectively. Although 
survival was similar, mTCV and mDSV were associated with higher rates of extrathyroidal extension and 
nodal metastasis in comparison to classic mPTC. mFHCC had over eight times the rate of distant 
metastases compared to mPTC and was associated with compromised 10-year disease specific survival 
(95.4 vs. 99.3%, P<0.001). Rates of extrapancreatic extension, nodal metastasis, and distant metastasis in 
PNETs ≤ 2 cm were 17.9%, 27.3%, and 9.1%, respectively. 
The incidence of many endocrine cancers is increasing, presumably due to increased detection. All 
histologies studied were capable of exhibiting aggressive behavior despite small tumor size. Further studies 
that specifically examine the risks and benefits of surgical therapy in small tumors may clarify future 
surgical decision making. 
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INTRODUCTION 
While advances in molecular biology have revolutionized how we understand and 
treat cancer, and targeted pharmacologic therapy has dramatically changed outcomes for 
patients with breast cancer, lung cancer, and leukemia among others, surgery remains the 
mainstay of cancer therapy with curative intent and remains an essential component of a 
patient’s hope for cure for those who present with localized disease.1-3 While the goal of 
cancer surgery, namely the total resection of disease, has remained unchanged, trends in 
the manner in which cancer presents itself has had dramatic impacts on the extent of 
surgical resection necessary to maintain acceptable oncologic outcomes. 
One of the most dramatic instances of this trend has been in the field of breast 
surgery. At the turn of the century, William Halsted established radical mastectomy as 
the standard of care for patients with breast cancer. A disfiguring procedure that involved 
resection of the entire breast along with the overlying skin, pectoralis major and minor 
muscles, and axillary lymphadenectomy, the Halsted radical mastectomy was developed 
in an era where many patients presented with bulky disease.4 With the widespread use of 
screening mammography in the 1980s, however, breast cancer is being detected earlier in 
its clinical course and in 1985, a randomized clinical trial, the NSABP B-04, proposed 
that equivalent outcomes could be achieved with simple mastectomy.5,6 Further still, the 
NSABP B-06 showed that in stage I and II breast cancers, lumpectomy in combination 
with radiation could also safely be performed without compromising oncologic 
outcomes.7 Today, approximately 75% of patients with stage I or II breast cancer choose 
breast conserving surgery.8 
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The trend towards earlier detection of cancers is not limited to the breast. An 
analysis of cancer incidence rates in the United States from 1999-2008 revealed that the 
greatest increases in incidence in pancreatic, liver, thyroid, renal cancer, and melanoma 
have occurred in localized tumors.9 Whereas the study of breast cancer has been 
facilitated by the social and statistical power afforded by its place as the most incident 
cancer in women, resulting in practice guidelines supported by randomized controlled 
trials, numerous barriers exist towards the optimal study of thyroid and pancreatic 
malignancies. The rarity of pancreatic cancer necessitates a collaborative multi-
institutional effort towards the performance of randomized controlled trials. This need is 
only magnified with the more uncommon subtypes of pancreatic cancer such as 
pancreatic neuroendocrine tumors (PNETs), where the majority of evidence for 
management comes from institutional series. In differentiated thyroid cancers, almost 
universally excellent outcomes obscure the study of patients with compromised 
outcomes, rendering randomized clinical trials sometimes unfeasible.10 Nevertheless, the 
possibility that small, localized tumors represent an increasing proportion of tumors as a 
whole deserves exploration, and a more precise characterization of these patients and 
their associated outcomes is necessary. This study seeks to accomplish these goals with 
respect to endocrine cancers of the thyroid and pancreas. 
Thyroid cancer 
The incidence of thyroid cancer has been rapidly increasing over the last 22 years, 
and notably, the largest rise in incidence has been observed in small tumors less than 1 
cm in size, also referred to as microcarcinomas.11 Much of this has been attributed to 
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increased detection, especially with respect to thyroid ultrasound.10,12 To date, most of the 
research on thyroid microcarcinoma has focused on the papillary histology, which is the 
most common form of thyroid cancer. Papillary thyroid microcarcinoma (mPTC), defined 
as papillary thyroid carcinoma (PTC) ≤ 1cm in size, is rapidly rising in incidence, 
accounting for 49% of the increase in PTC incidence from 1973 to 2002; currently it 
represents 43% of PTC in patients older than 45 years.13,14 These patients generally have 
an excellent prognosis, with 10- and 15- year disease specific survival in excess of 99%.15 
Because of the excellent outcomes in these patients, the decision to expose 
patients to the risk of thyroid surgery has to be carefully considered. In Japan, out of 
1,395 patients who were offered surgery or observation for mPTC, 340 chose 
observation. With a mean follow-up of 4 years, only 15.9% of observed tumors 
demonstrated enlargement, emphasizing the indolent nature of these tumors and calling 
into question the benefits of routine resection.16 
However, a subpopulation of patients with mPTC carry increased risk of mortality 
and benefit from total thyroidectomy.15 While risk factors such as age, race, nodal 
metastases, extrathyroidal invasion, and distant metastasis have helped characterize this 
population, the search continues for additional factors that can be used to identify patients 
with thyroid microcarcinoma who carry a poor prognosis.15,17 In thyroid cancers of all 
sizes, both aggressive variants of PTC as well as the other forms of differentiated thyroid 
carcinoma (DTC), including follicular (FTC) and Hurthle cell (HCC) carcinomas, have 
been shown to have compromised outcomes in comparison to PTC. However, in these 
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histologies, tumors ≤ 1cm in size have not been exclusively studied, and therefore there is 
a paucity of evidence with which to guide their treatment. 
Aggressive variants of papillary thyroid microcarcinoma 
Several histologic variants of PTC have been identified as having aggressive 
behavior in comparison to classic PTC, including diffuse sclerosing (DSV) and tall cell 
variants (TCV). First described in 1985, DSV is characterized by papillary morphology, 
diffuse involvement of the thyroid gland, prominent fibrosis, abundant psammoma 
bodies, squamous metaplasia, and lymphocytic infiltration easily confused with 
thyroiditis.18-20 It accounts for approximately 2-6% of PTC, classically occurs in young 
women, and is reported to have increased rates of multifocality, bilaterality, 
extrathyroidal extension, recurrence and nodal/distant metastasis.20-29 
TCV, first described in 1976, accounts for 3-12% of all PTC, and is characterized 
by a population of cells at least twice as tall as they are wide, composing 30-70% of total 
tumor cells.20,30-34 TCV has been reported to be larger than classic PTC on average, with 
higher rates of bilaterality, multifocality, extrathyroidal extension, recurrence, lymph 
node/distant metastasis, and decreased survival.24,29,35-42  
While it appears clear that DSV and TCV are aggressive, the extent to which 
DSV ≤ 1cm (mDSV) and TCV ≤1cm (mTSV) exhibit aggressive behavior remains an 
open question, and the optimal management of these tumors is currently unclear. Studies 
of aggressive variants of PTC largely consist of case reports and single-center case series, 
and two population-level studies that have been performed on the topic of DSV and TCV 
do not specifically address tumors ≤1cm in size.29,42 Similarly, in studies of mPTC, the 
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inclusion of aggressive morphologies is either variable or unclear, and it appears that no 
subset analysis of aggressive variants has been undertaken.15,17,43 
This study represents the first population-level analysis of aggressive variants of 
mPTC in which the incidence, demographic, clinical, and pathologic characteristics of 
mDSV and mTCV are compared with classic mPTC. 
Follicular and Hurthle cell microcaricnoma 
Follicular thyroid carcinoma (FTC) and Hurthle cell carcinoma (HCC) arise from 
the follicular cells of the thyroid and account for approximately 10% and 4% of thyroid 
malignancies, respectively.44 They are more likely than papillary thyroid carcinoma 
(PTC) to present with distant metastases, but nodal metastases are rare, which is 
consistent with the likely hematogenous dissemination of these tumors.45 Patients with a 
finding of follicular or Hurthle cell neoplasm on cytology generally have a 20-30% risk 
of malignancy, and definitive diagnosis requires histopathologic examination after 
surgical excision documenting capsular or vascular tumor invasion.46,47 
Follicular and Hurthle cell carccinomas less than 1 cm in size (mFTC and 
mFHCC, respectively) however, have not been exclusively studied. Just as with 
aggressive variants of papillary microcarcinoma, it is unknown whether these cancers 
have comparable outcomes, and evidence to guide their management is scarce. Therefore, 
their natural history is poorly understood and optimal treatment remains unclear. 
This study is the first to focus on follicular and Hurthle cell microcarcinoma 
(mFHCC) and examine the incidence, characteristics, and outcomes of mFHCC in 
comparison with mPTC. We also evaluate the independent effect of tumor histology on 
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survival, identify prognostic factors associated with disease-specific mortality, and 
determine whether patients benefit from total thyroidectomy and radioactive iodine 
(RAI). 
Pancreatic neuroendocrine tumors 
Pancreatic neuroendocrine tumors (PNETs) are rare pancreatic tumors that 
account for < 3% of pancreatic neoplasms.48-50 PNETs may be functional or non-
functional, and multiple grading systems have been proposed to predict their clinical 
behavior. According to the WHO classification, tumors can be designated as benign, of 
uncertain malignant potential, or malignant based on the presence of frank invasion or 
metastasis, vascular or perineural invasion, size, and proliferative activity.51 Hochwald, et 
al. proposed a different system, classifying PNETs as low or intermediate grade based on 
the presence of necrosis and proliferative activity alone.52 Regardless of the system used, 
however, the clinical behavior of PNETs remains unpredictable. Because tumors initially 
classified as benign may later display malignant behavior, there is a growing sentiment 
that all tumors greater than 0.5 cm in size have malignant potential.53 
 The increasing incidence of PNETs of all sizes over the last two decades is well-
documented.54 With increasingly sophisticated imaging technology, the incidental finding 
of small tumors has become more frequent. However, the incidence of small PNETs in 
the United States has yet to be reported on the population-level. Furthermore, studies of 
clinical outcomes in small PNETs have been limited to institutional series with mixed 
conclusions. Some authors advocate resection of all incidentally discovered, non-
functioning PNETs, while others propose observation to be a reasonable alternative.55,56 
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None have been able to analyze predictors of survival due to small sample size.56,57 
Additionally, the significance of nodal metastasis in small PNETs is unclear. Nodal 
metastasis has not been shown to be significant in multivariate analyses of survival in 
population-level studies.58,59 However, both AJCC and ENETS systems take nodal 
metastasis into account when staging PNETs and have been validated in PNETs of all 
sizes.60,61 Reported rates of nodal metastasis in PNETs ≤ 2 cm in size are variable, at 0%, 
9%, and 26%.56,60,62 
To our knowledge, this study is the first to exclusively analyze small PNETs on a 
population-level and examine incidence in addition to demographic, clinical, and 
pathologic characteristics of PNETs ≤ 2 cm in a surgical population. Our purpose is to 
determine the extent of increase in incidence of small PNETs in the United States, 
evaluate predictors of survival, and clarify the frequency and significance of nodal 
metastases in PNETs ≤ 2 cm. 
METHODS 
Data Source and Study Participants 
The data source for this study was the National Cancer Institute’s Surveillance, 
Epidemiology, and End Results (SEER) database, which provides population-based data 
on cancer incidence and survival from 18 registries (Atlanta, Connecticut, Detroit, 
Hawaii, Iowa, New Mexico, San Francisco-Oakland, Seattle-Puget Sound, Utah, Los 
Angeles, San Jose-Monterey, Rural Georgia, Alaska, Greater California, Kentucky, 
Louisiana, New Jersey, and Greater Georgia) and represents 28% of the United States 
population.63  
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Patients diagnosed with mTCV, mDSV, mFTC, mHCC, and mPTC, from 1988 to 
2009 were selected from all 18 registries using ICD-O-3 codes 8350 (DSV), 8344 (TCV), 
8330-8332 (mFTC), 8290 (mHCC), and 8050, 8260, 8341 (mPTC), in combination with 
“Extent of Disease” and “Collaborative stage” variables designating tumors ≤ 1cm in 
size. Of note, the ICD-O-3 code 8344 does not distinguish between tall cell and columnar 
cell variants of PTC, likely due to ambiguities in definition.64,65 Because histology has 
not been shown to be a significant prognostic factor distinguishing the two entities, 
mFTC and mHCC were compared to mPTC as one group.66 
Patients with PNETs diagnosed from 1988 to 2009 were selected from all 18 
registries using ICD-O-3 codes 8150 (islet cell carcinoma), 8246 (neuroendocrine 
carcinoma), and 8240-8249 (carcinoid tumor). Functional PNETs (insulinomas, etc.) 
were excluded from our study, as were mixed islet cell and exocrine adenocarcinomas. 
Because the SEER database is restricted to tumors with an ICD-O-3 behavior code of 2 
(in situ) or 3 (malignant), PNETs that were considered benign were unable to be included 
in our study. Our study was restricted to patients ≥ 18 years of age whose data were 
informed by active follow-up. 
Incidence data were obtained over the period of 1988-2009 from SEER 9 
registries (Atlanta, Connecticut, Detroit, Hawaii, Iowa, New Mexico, San Francisco-
Oakland, Seattle-Puget Sound, and Utah), which offers the most complete incidence data 
for this time period. Because TCV was first collected in the SEER database in 2001, 
incidence analysis of mTCV and mDSV was restricted to the years 2001-2009 to allow 
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for comparison. Rates were age-adjusted using the 2000 U.S. standard population. 
Annual percentage changes (APC) were calculated. 
Demographic variables of interest included patient age at diagnosis, gender, and 
race. Clinical variables of interest included surgical therapy, lymph node examination, 
radiation therapy, and survival status as of December 31, 2009. Survival time was 
calculated as time in years from diagnosis until death, date last known to be alive, or 
December 31, 2009, whichever came first. Overall and disease-specific survival rates 
were calculated. Pathologic variables of interest included tumor size, multifocality (for 
thyroid cancers), extraparenchymal extension, nodal metastasis, and distant metastasis. 
Extraparenchymal extension was defined as tumor invasion beyond the thyroid capsule 
for thyroid cancers or into peripancreatic tissue or adjacent organs or vessels for PNETs. 
Location of nodal metastasis in thyroid carcinomas were grouped corresponding to 
American Joint Committee on Cancer (AJCC) stages N1a (level VI) and N1b (levels I, II, 
III, IV, V, VII). 
With respect to surgery for PNETs, the SEER database did not distinguish 
between enucleation and partial pancreatectomy prior to 1997, and these patients were 
grouped under “enucleation/partial pancreatectomy, not otherwise specified.” 
Extrapancreatic extension was defined as tumor extension into peripancreatic tissue or 
adjacent organs or vessels. Pathology reports from patients diagnosed with non-
functioning neuroendocrine tumors of the pancreas from 1996-2012 were reviewed after 
identification through keyword search in an institutional pathology database at Yale-New 
Haven Hospital. Data regarding relevant clinical and pathologic variables were collected. 
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Statistical Analysis  
 Summary statistics were used to describe baseline characteristics. Chi square tests 
and analysis of variance were used to analyze categorical and continuous variables, 
respectively. Fischer’s exact test was used for analyze categorical variables with expected 
values less than 5. Survival was analyzed using the Kaplan-Meier method, and the log 
rank test was used to determine differences in survival that were statistically significant. 
Cox proportional hazards and stepwise binary logistic regression were used to identify 
factors independently associated with survival, extrathyroidal extension, nodal 
metastasis, and distant metastasis. Variables with a level of significance of P<0.1 on 
univariate analysis were included in the multivariate analysis. All tests were two-sided, 
and P<0.05 was considered statistically significant. 
 Incidence and trend analysis were performed by SEER*Stat version 8.0.1 
obtained from SEER (Bethesda, MD). All other analysis was performed with SPSS 
version 19 (SPSS, Inc., Chicago, IL). Because SEER data is publicly available and 
institutional data was recorded without identifiers, our study was deemed to be exempt 
from institutional review board approval. 
RESULTS 
Aggressive variants of papillary thyroid microcarcinoma 
There were 90 cases of mDSV, 97 cases of mTCV, and 18,260 cases of classic 
mPTC diagnosed during the study period. Patients with mTCV were followed for up to 9 
years, while mDSV and classic mPTC patients were followed for up to 22 years. Mean 
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follow-up for mDSV, mTCV, and classic mPTC was 7.0 years, 3.8 years, and 5.3 years, 
respectively. 
Incidence  
Incidence of classic mPTC increased from 1.42 per 100,000 in 2001 to 3.47 per 
100,000 in 2009, representing an annual percentage change (APC) of +11.8% 
(Ptrend<0.001). mTCV increased in incidence from 0.010 to 0.019 per 100,000 (APC 
+5.7%, Ptrend=0.153) and mDSV decreased in incidence from 0.0075 to 0.0067 per 
100,000 (APC -4.7%, Ptrend=0.315). 
Characteristics 
Clinical and pathologic characteristics are summarized in Tables 1 and 2. There 
were no significant demographic differences between patients with mDSV and mTCV 
compared to classic mPTC with respect to age, gender, or race. Patients with mTCV had 
lymph nodes examined more frequently compared to mPTC (63.9 % vs. 39.2%, 
P<0.001). Aggressive variants were more likely to receive radioiodine ablation (RAI) 
(40.0% mDSV vs. 39.2% mTCV vs. 29.1% mPTC, PmDSV=0.013, PmTCV<0.001); 
however, they were not statistically more likely to receive total thyroidectomy versus 
lobectomy compared to classic mPTC (70.0% mDSV vs. 78.4% mTCV vs. 71.8% mPTC, 
PmDSV=0.655, PmTCV=0.311). 
Compared to classic mPTC, mDSV had significantly higher rates of 
extrathyroidal extension (6.1% vs. 13.3%, P=0.004) and nodal metastasis (33.1% vs. 
57.1%, P=0.007). In patients with nodal metastasis, the ratio of N1a vs. N1b metastases 
was similar (50% vs. 50% mDSV, 59.0% vs. 41.0% mPTC, P=0.694). mDSV also tended 
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to be larger (5.8 mm vs. 5.3 mm, P=0.165), however the difference was not statistically 
significant. There were no differences between mDSV and mPTC with respect to rates of 
multifocality (33.3% vs. 14.0%, P=0.926) and distant metastasis (0.0% vs. 1.3%, 
P=0.519). 
The mTCV tumors tended to be larger on average compared to mPTC (7.1 mm  
vs. 5.3 mm, P<0.001), with significantly higher rates of multifocality (47.2% vs. 34.0%, 
P=0.018) and extrathyroidal extension (27.8% vs. 6.1%, P<0.001). Patients with mTCV 
also had higher rates of nodal metastasis (43.5% vs. 33.1%, P=0.081) and over four times 
the rate of distant metastasis compared to those with mPTC (2.1% vs. 0.5%, P=0.076). In 
patients with nodal metastasis, patients with mTCV tended to metastasize to the central 
compartment more frequently than those with mPTC (N1a vs. N1b, 76.5% vs. 23.5% 
mTCV, 59.0% vs. 41.0% mPTC, P=0.145), although the trend was not statistically 
significant. 
Survival 
 All-cause mortality occurred in 3.3% of mDSV (n=3), 1.0% of mTCV (n=1), and 
3.0% of classic mPTC (n=541), while disease specific deaths occurred in 1.1% of mDSV 
(n=1), 1.0% of mTCV (n=1), and 0.4% (n=69) of classic mPTC. 10-year disease specific 
survival for mDSV, mTCV, and classic mPTC was 100.0%, 98.5%, and 99.4% 
respectively, and univariate analysis of survival revealed no association between 
histologic variant and overall or disease specific survival (Figures 1-2). Due to the limited 
number of deaths in the mTCV and mDSV cohorts, multivariate analysis could not be 
performed. 
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Predictors of extrathyroidal extension and cervical lymph node metastasis 
 No statistically significant predictors of extrathyroidal extension or cervical 
lymph node metastases in mDSV were observed. In mTCV, extrathyroidal extension was 
independently associated with size >7mm (odds ratio [OR] 4.4, 95% CI 1.5-13.6) and 
nodal metastasis with multifocality (OR 5.4, 95% CI 1.3-23.4) and extrathyroidal 
extension (OR 5.8, 95% CI 1.3-25.4). 
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Table 1. Clinical characteristics of classic mPTC vs. mTCV vs. mDSV 
(SEER, 1988-2009) 
 Classic mPTC 
(n=18,260) 
mDSV 
(n=90) 
P value mTCV 
(n=97) 
P value 
Age   0.699  0.144 
Mean (SEM) 47.6 (0.1) 48.2 (1.4)  49.6 (1.4)  
Age 18-44 7,827 (42.9) 34 (37.8)  40 (41.2)  
Age 45-64 8,293 (45.4) 48 (53.3)  41 (42.3)  
Age ≥65 2,140 (11.7) 8 (8.9)  16 (16.5)  
Female gender 15,009 (82.2) 80 (88.9) 0.098 78 (80.4) 0.647 
Race   0.093  0.172 
White 13,430 (73.5) 57 (63.3)  82 (84.5)  
Hispanic 1,816 (9.9) 13 (14.4)  5 (5.2)  
Asian/Pacific Islander 1,761 (9.6) 13 (14.4)  7 (7.2)  
Black 919 (5.0) 7 (7.8)  3 (3.1)  
Other/Unknown 334 (1.8) 0 (0.0)  0 (0.0)  
Surgery   0.655  0.311 
No surgery 117 (0.6) 0 (0.0)  0 (0.0)  
Lobectomy 4,993 (27.3) 27 (30.0)  21 (21.6)  
Thyroidectomy 13,114 (71.8) 63 (70.0)  76 (78.4)  
Other/Unknown 36 (0.2) 0 (0.0)  0 (0.0)  
Lymph nodes examined   0.113  <0.001 
Not examined 11,503 (60.5) 62 (68.9)  35 (36.1)  
Examined 7,156 (39.2) 28 (31.1)  62 (63.9)  
Unknown 51 (0.3) 0 (0.0)  0 (0.0)  
Radiation   0.013  <0.001 
None 12,339 (67.6) 52 (57.8)  50 (51.5)  
Radioiodine ablation 5,308 (29.1) 36 (40.0)  38 (39.2)  
External beam radiation 107 (0.6) 2 (2.2)  4 (4.1)  
Radioactive implant 123 (0.7) 0 (0.0)  0 (0.0)  
Other/unknown 383 (2.1) 0 (0.0)  5 (5.2)  
Overall survival   0.720  0.532 
5 year 97.5 100.0  98.5  
10 yeara 94.7 97.6  98.5  
Disease specific survival   0.410  0.173 
5 year 99.6 90.9  98.5  
10 yeara 99.4 90.9  98.5  
Values in parentheses represent percentages unless otherwise designated 
aRepresents 9 year survival for mTCV 
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Table 2. Pathologic characteristics of classic mPTC vs. mTCV vs. mDSV 
(SEER, 1988-2009) 
 Classic mPTC 
(n=18,260) 
mDSV 
(n=90) 
P value mTCV 
(n=97) 
P value 
Size   0.165  <0.001 
Mean (mm) (SEM) 5.3 (0.02) 5.8 (0.3)  7.1 (0.3)  
Size ≤7 mm 12,427 (68.1) 63 (70.0)  49 (50.5)  
Size >7mm 5,341 (29.2) 27 (30.0)  43 (44.3)  
≤ 1cm, NOS 492 (2.7) 0 (0.0)  5 (5.2)  
Multifocality   0.926  0.018 
Unifocal 7,452 (40.8) 30 (33.3)  38 (39.2)  
Multifocal 3,837 (34.0) 15 (16.7)  34 (35.0)  
Unknown 6,971 (38.2) 45 (50.0)  25 (25.8)  
Extrathyroidal extension   0.004  <0.001 
Intrathyroidal 17,041 (93.3) 78 (86.7)  70 (72.2)  
Extrathyroidal 1,109 (6.1) 12 (13.3)  27 (27.8)  
Unknown 110 (0.6) 0 (0.0)  0 (0.0)  
Nodal metastasisa   0.007  0.081 
No positive lymph nodes 4,785 (66.9) 12 (42.9)  35 (56.4)  
≥ 1 positive lymph node 2,365 (33.0) 16 (57.1)  27 (43.6)  
Unknown 6 (0.0)  0 (0.0)  0 (0.0)  
Median (IQR) 2 (1-3) 4 (1-12)  2 (1-3)  
Distant metastasis   0.519  0.076 
No distant metastasis 17,948 (98.3) 90 (100.0)  95 (97.9)  
Distant metastasis 83 (0.5) 0 (0.0)  2 (2.1)  
Unknown 229 (1.3) 0 (0.0)  0 (0.0)  
Values in parentheses represent percentages unless otherwise designated 
aPercentage reflects fraction of patients whose lymph nodes were examined 
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Follicular and Hurthle cell microcarcinoma 
There were 564 cases of mFHCC (371 mFTC and 193 mHCC) and 22,174 cases 
of mPTC diagnosed during the study period. Patients with mFHCC and mPTC were 
followed for up to 22 years, with mean follow-up periods of 6.7 and 5.3 years, 
respectively. 
Incidence  
No statistically significant change in incidence was observed in mFTC, which 
decreased over the study period by an annual percentage change of -1.1% (Ptrend=0.241). 
Incidences of mHCC and mPTC increased significantly over the study period by 400.7% 
and 415.1% with annual percentage changes of 4.8% (Ptrend=0.003) and 8.7% 
(Ptrend<0.001), respectively. 
Characteristics 
Demographic, clinical, and pathologic characteristics are summarized in Table 3. 
There were no significant demographic differences between patients with mFHCC and 
mPTC with respect to average age or gender. Compared to mPTC, patients with mFHCC 
were more commonly of black race (5.1% vs. 8.3%, P=0.001) while less commonly 
Asian (9.2% vs. 6.6%, P=0.029). Rates of thyroidectomy for mFHCC and mPTC were 
not significantly different, but patients with mFHCC were less likely to have lymph 
nodes examined (27.8% vs. 38.5% mPTC, P<0.001) and more likely to receive 
radioactive iodine (33.0% vs. 28.4% mPTC, P<0.001). 
Compared to mPTC, mFHCC had similar rates of multifocality and extrathyroidal 
extension. On average, mFHCC tumors tended to be larger than mPTC (6.3mm vs. 
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5.3mm, P<0.001), with more than eight times the rate of distant metastasis (4.1% vs. 
0.5%, P<0.001). Nodal metastases were less frequent (9.6% vs. 33.5% mPTC, P<0.001), 
although the distribution between level N1a and N1b lymph nodes was similar.  
Subset analysis comparing characteristics of mFTC and mHCC are summarized in 
Table 4. On average, patients with mHCC were older than those with mFTC (53.3 years 
vs. 49.3 years, P=0.004), had lower rates of distant metastasis (1.6% vs. 5.4%, P=0.030) 
and higher rates of lymph node examination (35.2% vs. 24.0%, P=0.005). There were no 
significant differences between mFTC and mHCC with respect to patient gender, race, 
tumor size, multifocality, extrathyroidal extension, nodal metastasis, extent of thyroid 
surgery, and radioactive iodine administration. 
Survival 
 All-cause mortality occurred in 11.9% of patients with mFHCC and 5.2% of 
patients with mPTC; disease-specific mortality occurred in 3.5% of patients with mFHCC 
and 0.4% of patients with mPTC. Disease-specific survival (DSS) was decreased in 
mFHCC compared to mPTC at 5 years (97.0% vs. 99.6%), 10 years (95.4% vs. 99.3%), 
and 15 years (94.4% vs. 99.0%, P<0.001) (Figure 3). In a combined cohort of mFHCC 
and mPTC, follicular or Hurthle cell histology remained an independent risk factor of 
reduced survival (HR 5.30, P<0.001) after adjustment for patient age, type of surgery, 
type of radiation, extrathyroidal extension, nodal metastasis, and distant metastasis (Table 
5). 
In patients with mFHCC, patient age ≥ 65 years (HR 9.11, P=0.011), 
extrathyroidal extension (HR 9.55, P<0.001), and necessitating external beam radiation 
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(HR 35.62, P<0.001) remained independent predictors of decreased disease-specific 
survival after adjustment (Figures 4-5, Table 4). Patients with mFHCC were further 
stratified by independent predictors of survival as determined by multivariate analysis. 5-
year disease-specific survival in patients with 0 risk factors (age < 65 years without 
extrathyroidal extension), 1 risk factor (age ≥ 65 years or extrathyroidal extension), or 2 
risk factors (age ≥ 65 years and extrathyroidal extension) was 99.2%, 95.1% and 83.3%, 
respectively (P<0.001) (Figure 4).  
Extent of thyroidectomy and radioactive iodine 
 In patients with mFHCC, no statistically significant benefit in disease-specific 
survival was observed with total thyroidectomy compared to lobectomy (10-year disease- 
specific survival 93.7% vs. 97.3%, respectively, P=0.523) or radioactive iodine compared 
to no radioactive iodine (10-year disease-specific survival 95.6% vs. 98.7%, respectively, 
P=0.097). Subset analysis of high risk patients with either 1 or 2 risk factors also revealed 
no benefit with total thyroidectomy (10-year disease-specific survival 80.5% vs. 90.5%, 
respectively, P=0.584), while survival was worse in patients who received radioactive 
iodine (5-year disease-specific survival 85.0% vs. 98.7%, respectively, P=0.027). 
Predictors of extrathyroidal extension, nodal metastasis, and distant metastasis 
 After adjustment, tumor size >7mm remained the only independent risk factor for 
extrathyroidal extension in mFHCC (OR 2.45, P=0.020; reference, no extrathyroidal 
extension), and male gender remained the only independent risk factor for nodal 
metastases (OR 5.62, P=0.002; reference, female). Independent risk factors for distant 
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metastasis included patient age ≥ 65 years (OR 9.40, P<0.001; reference, age 18-44 
years) and Asian race (OR 9.18, P<0.001; reference, White). 
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Table 3. Characteristics of patients with mFHCC vs. mPTC (SEER, 1988-2009) 
 mFHCC 
(n=564) 
mPTC 
(n=22,174) 
P value 
Demographic Age (years)   0.011 
 Mean (SEM) 50.7 (0.7) 49.2 (0.1)  
    18-44 37.4 38.8  
    45-64 41.1 46.3  
    ≥65 21.5 14.9  
 Female gender 77.7 80.7 0.070 
 Race   0.001 
    White 76.2 74.7  
    Hispanic 7.8 9.5  
    Asian 6.6 9.2  
    Black 8.3 5.1  
    Other/Unknown 1.1 1.6  
Clinical Surgery   0.183 
    No surgery 1.2 0.9  
    Lobectomy 30.9 27.9  
    Thyroidectomy 67.7 71.0  
 Lymph nodes examined 27.8 38.5 <0.001 
 Radiation   <0.001 
    None 60.5 68.1  
    Radioiodine ablation 33.0 28.4  
    External beam radiation 1.8 0.7  
Pathologic Size   <0.001 
 Mean (mm) (SEM) 6.3 (0.12) 5.3 (0.02)  
    ≤7mm 53.5 68.8  
    >7-10mm 42.4 28.5  
    ≤ 10mm, NOS 4.1 2.7  
 Multifocal 28.6 33.9 0.071 
 Extrathyroidal extension 5.7 6.0 0.837 
 Nodal metastasis*    
    ≥ 1 positive lymph node 9.6 33.4 <0.001 
    Median (IQR) 2 (1-5) 2 (1-4)  
    Level   0.954 
    N1a 57.1 58.1  
    N1b 42.9 41.9  
 Distant metastasis 4.1 0.5 <0.001 
Survival Overall survival   <0.001 
    5 year 91.3 95.6  
    10 year 83.4 90.8  
    15 year 80.9 85.8  
 Disease-specific survival   <0.001 
    5 year 97.0 99.6  
    10 year 95.4 99.3  
    15 year 94.4 99.0  
Values presented are percentages of given sample sizes unless otherwise designated. Unknowns were 
excluded from statistical analysis. Follicular and Hurthle cell microcarcinoma, mFHCC; papillary thyroid 
microcarcinoma, mPTC. 
*Represents percentage of patients whose lymph nodes were examined. 
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Table 4. Characteristics of patients with mFTC vs. mHCC (SEER, 1988-2009) 
 mFTC 
(n=371) 
mHCC 
(n=193) 
P value 
Age (years)   0.004 
Mean (SEM) 49.3 (0.8) 53.3 (1.1)  
   18-44 42.0 28.5  
   45-64 38.3 46.6  
   ≥65 19.7 24.9  
Female gender 79.0 75.1 0.298 
Race   0.168 
   White 74.1 80.3  
   Hispanic 7.3 8.8  
   Asian 7.5 4.7  
   Black 9.7 5.7  
   Other/Unknown 1.3 0.5  
Surgery   0.054 
   No surgery 1.6 0.5  
   Lobectomy 33.7 25.4  
   Thyroidectomy 64.4 74.1  
Lymph nodes examined 24.0 35.2 0.005 
Radiation   0.803 
   None 61.7 58.0  
   Radioactive iodine 32.3 34.2  
   External beam radiation 1.9 1.6  
   Other/unknown 4.0 6.2  
Size   0.446 
Mean (mm) (SEM) 6.2 (0.1) 6.4 (0.2)  
   ≤7 mm 54.4 51.8  
   >7-10 mm 41.0 45.1  
   ≤ 10 mm, NOS 4.6 3.1  
Multifocal 26.3 32.3 0.297 
Extrathyroidal extension 4.9 7.3 0.270 
Nodal metastasis*    
   ≥ 1 positive lymph node 7.9 11.8 0.410 
Distant metastasis 5.4 1.6 0.030 
Values presented are percentages of given sample sizes unless otherwise designated. 
Unknowns were excluded from statistical analysis. Follicular thyroid microcarcinoma, 
mFTC, Hurthle cell microcarcinoma, mHCC 
*Represents percentage of patients whose lymph nodes were examined. 
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Table 5. Multivariate analysis of factors independently associated with disease specific 
mortality for patients with differentiated thyroid microcarcinoma (mPTC, mFTC and 
mHCC combined) (SEER, 1988-2009) 
 Hazard ratio 95% Confidence interval P value 
Histology    
   Papillary histology 1.00   
   Follicular or Hurthle histology 5.30 2.78-10.10 <0.001 
Age (years)    
   18-44  1.00   
   45-64  4.84 2.33-10.07 <0.001 
   ≥65 21.7 10.38-45.31 <0.001 
Surgery    
   No surgery 5.32 1.18-23.92 0.029 
   Lobectomy 1.00   
   Thyroidectomy 1.13 0.67-1.95 0.624 
Radiation    
   No radiation 1.00   
   Radioactive iodine 1.04 0.63-1.73 0.877 
   External beam radiation 5.44 2.45-12.10 <0.001 
Extrathyroidal extension    
   No 1.00   
   Yes 4.63 2.77-7.74 <0.001 
Nodal metastasis    
   No 1.00   
   Yes 3.36 1.93-5.82 <0.001 
Distant metastasis    
   No 1.00   
   Yes 12.86 5.26-31.44 <0.001 
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Figure 3. Disease-specific survival of mPTC and mFHCC (SEER, 1988-2009). Papillary 
thyroid microcarcinoma, mPTC; follicular and Hurthle cell microcarcinoma, mFHCC. 
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Figure 4. Disease-specific survival of follicular and Hurthle cell microcarcinoma by age 
(SEER, 1988-2009). 
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Figure 5. Disease-specific survival of follicular and Hurthle cell microcarcinoma by 
extrathyroidal extension (SEER, 1988-2009) 
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Pancreatic neuroendocrine tumors ≤ 2 cm in size 
1,371 cases of non-functioning PNETs were identified in the SEER database, 
including 263 tumors ≤ 2 cm and 1,108 tumors > 2 cm; patients were followed for up to 
21.7 years, with a mean follow-up of 4.2 years. In the institutional pathology database, 79 
cases of non-functioning PNETs were identified, including 43 tumors ≤ 2 cm and 36 
tumors > 2 cm. 
Incidence  
The annual incidence of PNETs ≤ 2 cm versus > 2 cm from 1988-2009 is shown 
in Figure 10. The incidence of PNETS ≤ 2 cm increased by 710.4% (annual percentage 
change [APC] 12.8%, P<0.0001) over the 22 year study period, while the incidence of 
PNETs > 2 cm in size increased by 343.6% (APC 7.5%, P<0.0001). PNETs ≤ 2 cm 
accounted for 20.2% of total PNET diagnoses in 2009, in contrast to 12.3% of total 
PNET diagnoses in 1988. 
Characteristics—SEER 
Demographic, clinical, and pathologic characteristics from the SEER database are 
summarized in Tables 10 and 11. PNETs ≤ 2 cm were more frequently well-differentiated 
(78.9% vs. 59.8%, P<0.001), with decreased rates of extrapancreatic extension (17.9% 
vs. 43.3%, P<0.001) and distant metastasis at presentation (9.1% vs. 24.2%, P<0.001) 
compared to PNETS > 2 cm. 
PNETs ≤ 2 cm were less likely to have lymph nodes examined compared to 
PNETs > 2 cm (71.1% vs. 82.4%, P<0.001), and although the difference was not 
statistically significant, PNETs ≤ 2 cm also tended to have fewer nodes examined 
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(median[interquartile range] 6[3-14] vs. 8[3-14] nodes, P=0.282). PNETs ≤ 2 cm had 
lower rates of nodal metastasis compared to PNETs > 2 cm (27.3% vs. 54.1%, P<0.001). 
In patients with node positive disease, those with PNETs ≤ 2 cm had a smaller number of 
positive nodes (2[1-3] vs. 2[1-5], P=0.006) compared to PNETS > 2 cm. In tumors of all 
sizes, multivariate analysis revealed nodal metastasis to be less likely in PNETs ≤ 2 cm 
(hazard ratio [HR] 0.3, P<0.001; reference, 2.6-5.0 cm), but more likely in patients with 
poorly differentiated tumors (HR 2.2, P=0.010; reference, well differentiated) and 
extrapancreatic extension (HR 3.3, P<0.001). Subset analysis of PNETs ≤ 2 cm revealed 
nodal metastasis to be more likely in tumors with extrapancreatic extension (HR 6.7, 
P<0.001), but less likely in patients ≥ 65 years of age (HR 0.2, P=0.008; reference, age < 
45 years). 
Characteristics—Institutional series 
Demographic, clinical and pathologic characteristics from the institutional 
pathology database are summarized in Table 12. Rates of nodal metastasis in PNETs ≤ 2 
cm and > 2 cm were 5.7% (2 of 35) and 28.6% (10 of 35), respectively. Both nodal 
metastases in PNETs ≤ 2 cm were associated with tumors 2 cm in size; no nodal 
metastasis was observed in PNETs < 2 cm. 
Survival—SEER  
Review of SEER data showed the all-cause mortality rate to be 13.7% in patients 
with PNETs ≤ 2 cm and 30.8% in patients PNETs > 2 cm; disease-specific mortality 
occurred in 10.0% of patients with PNETs ≤ 2 cm and 24.9% of patients PNETs > 2 cm. 
Disease specific survival at 5, 10, and 15 years for PNETs ≤ 2 cm was 89.7%, 80.0%, and 
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70.6%, and for PNETs > 2 cm was 75.3%, 58.7%, and 44.9% (P<0.001). In PNETs ≤ 2 
cm, decreased disease specific survival was associated with race, grade, and 
extrapancreatic extension on univariate analysis. After adjustment, decreased disease 
specific survival was associated with higher grade (moderately differentiated, HR 37.2, 
P=0.007; poorly differentiated, HR 94.2, P=0.003; reference group, well differentiated), 
and minority race (Asian, HR 30.2, 0.003; Black, HR 46.4, P=0.015; reference group, 
white) on multivariate analysis. Race was not a significant predictor of survival in PNETs 
> 2 cm on univariate analysis (P=0.187). 
PNETs ≤ 2 cm were further subdivided into groups of 0.1-0.5 cm, 0.6-1.0 cm, 
1.1-1.5 cm, and 1.6-2.0 cm, and nodal examination, nodal metastasis, and disease specific 
survival were analyzed (Table 13). 
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Table 10. Demographic and Clinical Characteristics of PNETs ≤ 2 cm vs. > 2 cm, SEER 
1988-2009 
 Size ≤ 2 cm 
(n=263) 
Size > 2 cm 
(n=1,108) 
P 
Age   0.488 
Mean [years] (SEM) 55.4 (0.8) 56.0 (0.4)  
Age 18-44 22.1 19.7  
Age 45-64 49.4 52.2  
Age ≥65 28.5 28.2  
Female gender 51.0 48.0 0.392 
Race   0.512 
White 72.6 75.3  
Hispanic 6.1 7.4  
Asian 8.0 6.0  
Black 11.4 10.1  
Other/Unknown 1.9 1.2  
Surgery   <0.001 
Enucleation 9.5 2.5  
Partial pancreatectomy 44.1 40.7  
Enucleation/Partial pancreatectomy, NOS 3.4 3.2  
Pancreaticoduodenectomy 30.8 38.7  
Total pancreatectomy 6.1 9.7  
Other 6.1 5.1  
Nodal examination   <0.001 
≥ 1 lymph node examined 71.1 82.4  
Median (IQR) 6 (3-14) 8 (3-14)  
Radiation   0.111 
None 96.6 92.7  
External beam radiation 2.3 5.2  
Other 0.4 0.5  
Unknown 0.8 1.5  
Overall survival   <0.001 
5 year 85.2 69.1  
10 year 75.2 51.8  
15 year 58.2 36.0  
Disease specific survival   <0.001 
5 year 89.7 75.3  
10 year 80.0 58.7  
15 year 70.6 44.9  
Values presented are percentages of given sample sizes unless otherwise designated. 
Unknowns were excluded from statistical analysis. PNET, pancreatic neuroendocrine 
tumor; SEER, Surveillance, Epidemiology, and End Results database; SEM, standard 
error of the mean; IQR, interquartile range 
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Table 11. Pathologic Characteristics of PNETs ≤ 2 cm vs. > 2 cm, SEER 1988-2009 
 Size ≤ 2 cm 
(n=263) 
Size > 2 cm 
(n=1,108) 
P 
Mean size [cm], (SEM) 1.40 (0.03) 5.76 (0.10) <0.001 
Histology   0.001 
Neuroendocrine carcinoma 27.4 34.0  
Islet cell carcinoma  61.6 60.7  
Carcinoid 11.0 5.2  
Location   0.018 
Head 29.3 33.2  
Body 16.0 10.6  
Tail 30.0 35.9  
Other 24.7 20.2  
Grade   <0.001 
Well-differentiated 41.1 34.4  
Moderately differentiated 6.8 14.2  
Poorly differentiated 1.9 6.9  
Undifferentiated 2.3 2.1  
Unknown 47.9 42.5  
Extrapancreatic extension 17.9 43.3 <0.001 
Nodal metastasis   <0.001 
≥ 1 positive lymph nodea 27.3 54.1  
Median (IQR) 2 (1-3) 2 (1-5)  
Distant metastasis 9.1 24.2 <0.001 
Values presented are percentages of given sample sizes unless otherwise designated. 
Unknowns were excluded from statistical analysis. PNET, pancreatic neuroendocrine 
tumor; SEER, Surveillance, Epidemiology, and End Results database; SEM, standard 
error of the mean; IQR, interquartile range 
aRepresents percentage of patients who underwent nodal examination 
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Table 12. Characteristics of PNETs ≤ 2 cm vs. > 2 cm, institutional series 1996-2012 
 Size ≤ 2 cm 
(n=43) 
Size > 2 cm 
(n=36) 
P 
Age   0.105 
Mean [years], (SEM) 58.9 (1.4) 54.9 (2.2)  
Age 18-44 7.0 22.2  
Age 45-64 62.8 52.8  
Age ≥65 30.2 25.0  
Female gender 58.1 44.4 0.225 
Surgery   0.051 
Enucleation 4.7 0.0  
Partial pancreatectomy, NOS 7.0 5.6  
Distal pancreatectomy w/o splenectomy 30.2 8.3  
Distal pancreatectomy w/ splenectomy 30.2 55.6  
Pancreaticoduodenectomy 27.9 30.6  
Nodal examination   0.027 
≥ 1 lymph node examineda 81.4 97.2  
Median (IQR) 10 (5-16) 13 (6-22)  
Extrapancreatic extension  7.0 36.1 0.001 
Nodal metastasis   0.011 
≥ 1 lymph node positive 5.7 28.6  
Median (IQR) 1.5 (1-2) 3.5 (2-7)  
Lymphovascular invasion 7.0 61.1 <0.001 
Perineural invasion 11.6 19.4 0.335 
Multifocal 4.7 5.6 0.855 
Mitotic rate   0.008 
<2 / 10 HPF 55.8 36.1  
2-5 / 10 HPF 2.3 19.4  
> 5 / 10 HPF 0.0 5.6  
Unknown 41.9 38.9  
Ki67   0.101 
<2 % 27.9 13.9  
2-5 % 14.0 13.9  
> 5 % 4.7 16.7  
Unknown 53.5 55.6  
Values presented are percentages of given sample sizes unless otherwise designated. 
Unknowns were excluded from statistical analysis. PNET, pancreatic neuroendocrine 
tumor; SEM, standard error of the mean; IQR, interquartile range; HPF, high-powered 
field 
aRepresents percentage of patients who underwent nodal examination
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Table 13. Nodal examination, nodal metastasis, and disease specific survival in PNETs ≤ 
2 cm, SEER 1988-2009 (n=260)a 
Tumor size Nodal 
examination 
(%) 
Nodal 
metastasis 
(%)b 
Disease specific survival (%) 
5-year 10-year 15-year 
0.1-0.5 cm (n=16) 75.0 25.0 100.0 100.0 66.7 
0.6-1.0 cm (n=51) 58.8 16.7 94.7 94.7 94.7 
1.1-1.5 cm (n=94) 69.1 21.5 95.1 75.5 75.5 
1.6-2.0 cm (n=99) 80.8 36.3 82.4 76.1 68.4 
PNET, pancreatic neuroendocrine tumor; SEER, Surveillance, Epidemiology, and End 
Results 
aTwo patients with tumor size recorded as “2 cm, not otherwise specified” and one 
patient with unknown nodal status were excluded 
bReflects percentage of patients who underwent nodal examination 
 
 
Figure 10. Incidence of pancreatic neuroendocrine tumors ≤ 2 cm and > 2 cm in size, 
SEER 1988-2009; PNET, pancreatic neuroendocrine tumor; SEER, Surveillance, 
Epidemiology, and End Results database; APC, annual percentage change 
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DISCUSSION 
Aggressive variants of papillary thyroid microcarcinoma 
 To our knowledge, this study represents the first population-level analysis of 
aggressive variants of mPTC. We found the incidences of mTCV and mDSV are not 
increasing to the same degree as mPTC, and that mTCV and mDSV exhibit aggressive 
features despite their small size. In comparison to mPTC, mDSV was characterized by 
higher rates of extrathyroidal extension and nodal metastasis, while mTCV was 
characterized by higher rates of multifocality and extrathyroidal extension. Both 
multifocality and extrathyroidal extension predicted nodal metastasis in mTCV. While no 
association between histologic variant and overall or disease specific survival was found, 
our study was likely underpowered to detect such a difference. 
 The rapidly rising incidence of mPTC is well established, the most common type 
of PTC being microcarcinoma in patients older than 45 years.11,13,14  However, no data on 
the incidence of aggressive variants of mPTC have been reported. In a population-level 
analysis of DSV and TCV of all sizes, Kazaure, et al. reported that the incidence of 
aggressive variants was outpacing that of PTC in the US, attributing the increase to 
improved detection and accuracy in the diagnosis of DSV and TCV.29  A population-level 
analysis of thyroid cancers in Parma, Italy similarly showed a significant increase in TCV 
from 1998-2009g.67  Therefore, the 79.9% increase in incidence of mTCV observed in 
our study is likely real, although limited by sample size. The incidence of mDSV appears 
to have been more level during the study period. 
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 Management of aggressive variants is controversial, and current guidelines from 
the American Thyroid Association do not address the extent of thyroid surgery for 
patients with aggressive variants.46  Overall, studies of DSV and TCV show that 
prognosis is worse, with increased recurrence and decreased survival.26,29,40-42,68  Some 
authors have suggested that this difference should be attributed to higher rates of 
aggressive pathologic features rather than variant histology, and they do not recommend 
aggressive treatment based on histology alone.39,68,69  Contrary studies that control for 
these aggressive features show that histology remains an independent risk factor for 
adverse outcomes, and many advocate total thyroidectomy with prophylactic central 
lymphadenectomy in aggressive variants regardless of tumor size.20,28,40,42,70 None of 
these studies have examined mDSV and mTCV specifically, and it is unclear whether 
histology alone warrants more extensive surgery in tumors ≤ 1cm. In our study, no 
differences in survival were observed between the different histologies, suggesting 
histology alone may not warrant extensive surgery. However, because mDSV and mTCV 
appear to exhibit aggressive characteristics with increased rates of multifocality, 
extrathyroidal extension, and nodal metastasis, and we postulate that tumor recurrence is 
likely. As a result, in patients diagnosed pre- or intraoperatively with micro-aggressive 
variants of PTC, we recommend total thyroidectomy, central lymphadenectomy, and 
post-operative RAI, and for those diagnosed postoperatively after initial lobectomy, 
completion thyroidectomy and post-operative RAI. Performing a redo prophylactic 
ipsilateral central lymphadenectomy at the time of completion thyroidectomy is not 
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common practice, even though it has been shown to be safe if performed in a high-
volume center with experienced surgeons.71 
Preoperative diagnosis of DSV and TCV is difficult.20,70  TCV and DSV have 
unique cytopathologic characteristics, and although diagnostic criteria have not been 
rigorously evaluated, several reports indicate that finding tadpole-shaped cells or 
inflammation and squamous metaplasia on FNA can raise preoperative suspicion of TCV 
and DSV, respectively.31,32,34,72,73  Nevertheless, preoperative diagnosis of variant 
histologies on fine needle aspiration (FNA) is limited, and it is common for patients to be 
diagnosed post-operatively after histopathologic examination. Our study suggests that 
aggressive features found in DSV and TCV persist in tumors ≤ 1cm in size, and that 
therefore mDSV and mTCV are disproportionately represented in microcarcinomas 
presenting with size >7mm, multifocality, extrathyroidal extension, and nodal 
metastases.21-29,35-42  Therefore, in patients with aggressive pre- or intraoperative findings, 
such as a high degree of sclerosis, obvious extrathyroidal extension or evidence of 
clinically positive lymph nodes, clinicians should have a high degree of suspicion for an 
aggressive variant and be prepared to perform a more aggressive operation with respect 
to the extent of thyroid surgery and possible lymphadenectomy. 
 The use of molecular tests is becoming more common, and may aid in the 
preoperative diagnosis of more aggressive variants of PTC. BRAF V600E has been 
shown in mPTC to be associated with tumor size, extrathyroidal extension, multifocality, 
nodal metastases, and advanced stage.74-77  Furthermore, the mutation is highly prevalent 
in TCV, with reports ranging from 66-100%.74,77-81. While the molecular pathogenesis of 
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DSV is less well studied, RET/PTC rearrangements appear to predominate.82  More work 
needs to be done on the molecular testing of these variants in order to provide valuable 
diagnostic, prognostic, and therapeutic information.83 
The limitations of this study include those inherent to the SEER database, such as 
coding errors, limited data for variables where collection began only recently (for 
example, multifocality and location of cervical lymph node metastases), and lack of data 
on variables not collected by SEER (for example, BRAF/RET gene status, central vs. 
lateral lymphadenectomy, reoperation, and recurrence). Because mDSV and mTCV are 
rare tumors, our study, while the largest to date, may still be underpowered to document 
more subtle differences between mDSV, mTCV, and mPTC. The strengths of our study 
include its large relative sample size and the use of population-level data. 
Overall, mDSV and mTCV are rare tumors that share many characteristics with 
histologically identical tumors > 1cm in size. They tend to be more aggressive compared 
to classic mPTC, and while they do not appear to differ with respect to survival, given 
our findings of higher nodal involvement and extrathyroidal extension, we postulate that 
they may have higher recurrence rates. Treatment with total thyroidectomy, possible 
central lymphadenectomy, and postoperative RAI may be indicated. Long term data on 
recurrence and more highly powered studies of survival will elucidate the prognosis of 
patients with mDSV and mTCV. Further understanding of the molecular pathogenesis of 
mDSV and mTCV will improve future diagnostic and prognostic power. 
Follicular and Hurthle cell microcarcinoma 
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 To our knowledge, this study represents the first population-level analysis of 
mFHCC. We found that more than 1 in 25 patients with mFHCC present with distant 
metastasis, and that patients with mFHCC had compromised survival compared to those 
with mPTC, which was most marked in older patients and those whose tumors exhibited 
extrathyroidal extension. Furthermore, no survival benefit was observed with total 
thyroidectomy over lobectomy. 
Microcarcinomas of the thyroid have been rapidly rising in incidence, and while 
this increase is largely due to mPTC, changes in incidence of mHCC and mFTC remain 
undefined. With respect to HCC, Goffredo, et al. showed that the incidence of tumors of 
all sizes has increased; however,  the incidence of mHCC and its relation to the rise in 
mPTC has not been previously reported.84 In our study, we found that the incidence of 
mHCC increased dramatically over the last 25 years on an order similar to that of mPTC. 
Therefore, while mHCC represents a small fraction of thyroid microcarcinomas overall, 
its incidence is rapidly rising in parallel with mPTC, suggesting mHCC may be subject to 
similar epidemiologic factors. In contrast, the incidence of FTC, after decreasing in 
incidence likely due to the dissemination of iodine supplementation in the 1920-1930s, 
may be continuing to decline.45 In a recent series of 258 patients treated over a 2 year 
period, FTC accounted for only 2.7% of thyroid carcinomas after pathologic review, 
which the authors attributed to increasing recognition of the follicular variant of PTC.85 
In our study, mFTC accounted for less than 2% of thyroid microcarcinomas and its 
incidence did not change significantly over the study period, confirming that mFTC is a 
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rare tumor with a stable incidence that is subject to epidemiologic factors distinct from 
mPTC and mHCC. 
It is well known that FTC disseminates hematogenously; as a result, distant 
metastasis is relatively common, found in approximately 10% of patients at presentation, 
while nodal metastasis is rare.86 Studies of HCC reveal similar rates of distant 
metastasis.66 However, none of these studies exclusively analyzed tumors ≤ 1cm in size, 
and therefore the natural history of mFHCC is largely unknown. In our study, patients 
with mFTC and mHCC presented with distant metastasis eleven and three times more 
frequently than patients with mPTC, respectively, with the rate of distant metastasis in 
mFTC even surpassing that of medullary thyroid microcarcinoma.87 Distant metastasis is 
therefore a unique feature of follicular and Hurthle cell histologies regardless of tumor 
size and can occur early in their natural history. 
Our study also found that compared to mPTC, patients with mFHCC have 
compromised survival. It is known that survival in FTC and HCC in general is decreased 
compared to that of PTC.44,88 However, our finding that follicular or Hurthle cell 
histology was independently associated with mortality confirms that this difference 
persists even in small tumors. Additional predictors of increased mortality identified in 
FHCC tumors of all sizes include older patient age, male gender, large tumor size, 
extrathyroidal extension, nodal metastasis, and distant metastasis.66,86,89-94 Our study 
found patient age ≥ 65 years and extrathyroidal extension to be the two factors most 
predictive of mortality in tumors ≤ 1cm in size, and notably, 5- and 10-year survival rates 
of patients with mFHCC and one risk factor approached survival rates in studies of FTC 
41 
 
 
 
 
 
of all sizes. Overall, the high rate of distant metastasis and compromised survival 
exhibited in mFHCC compared to mPTC refutes any notion that these tumors can be 
dismissed on account of their small size. 
In contrast to mPTC, which frequently can be diagnosed on fine needle aspiration, 
a diagnosis of mFHCC cannot be made until capsular or vascular invasion is identified in 
a surgical specimen. The risk of malignancy in patients with a cytologic diagnosis of 
follicular or Hurthle cell neoplasm is 20-30%; however, large tumor size (> 4 cm), among 
other factors such as family history, history of irradiation, and marked atypia on biopsy, 
have been associated a higher risk of malignancy.95 Patients with a follicular or Hurthle 
cell neoplasm and a small nodule ≤ 1 cm in size may therefore be more likely to be 
dismissed as having a lower risk of malignancy, which may result in delays in treatment. 
Given the higher rates of distant metastasis and compromised survival for mFHCC 
observed in this study, we recommend that the possibility of harboring mFHCC should be 
taken seriously, and definitive diagnostic surgery should be performed. 
An improved understanding of the molecular biology of these tumors may help to 
raise suspicion of malignancy, especially in tumors ≤ 1 cm where suspicion is otherwise 
low. RAS point mutations and PAX8-PPARγ rearrangements are common in follicular 
and Hurthle histologies. In a series of 1056 consecutive fine needle aspiration samples, a 
panel of molecular tests including RAS and PAX8- PPARγ was able to predict 
malignancy in patients with a cytologic diagnosis of follicular or Hurthle cell neoplasm 
with a positive predictive value of 87%.96 Molecular diagnostics may therefore have a 
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unique role in diagnosing malignancy in patients with follicular or Hurthle cell neoplasms 
≤ 1 cm where the risk of malignancy is otherwise low. 
The optimal extent of thyroid surgery to be performed in mFHCC is unclear. 
Guidelines from the American Thyroid Association suggest lobectomy to be the 
procedure of choice for mPTC in low-risk patients, but does not specifically comment on 
microcarcinomas with follicular or Hurthle histologies.46 Therefore, the necessity of 
completion thyroidectomy if mFHCC is diagnosed post-operatively is unclear. In our 
study, no survival benefit was observed in patients undergoing  thyroidectomy over 
lobectomy; therefore, lobectomy likely represents an adequate intervention for the 
purposes of diagnosis and treatment in patients with tumors ≤ 1 cm and a diagnosis of 
follicular or Hurthle cell neoplasm.  
In regard to radioactive iodine administration, patients with FTC who have 
clinical indications for radio iodine treatment in the adjuvant setting have demonstrated 
some benefits; by convention, radioactive iodine also is administered to patients with 
HCC even though only a minority of these tumors demonstrates iodine avidity.84 In our 
study, radioactive iodine treatment did not confer a survival benefit in patients with 
mFHCC, and therefore may not be necessary for tumors ≤ 1 cm in size. 
The limitations of this study include those inherent to the SEER database, such as 
coding errors, limited data for variables where collection began only recently (for 
example, multifocality and location of cervical lymph node metastases), and lack of data 
on variables not collected by SEER (for example, molecular markers, central vs. lateral 
lymphadenectomy, reoperation, persistence of disease, and recurrence). Because the 
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study was retrospective, it is difficult to interpret the lack of survival benefit with total 
thyroidectomy and radioactive iodine administration, as treatments were not 
standardized. SEER also lacks a centralized review of pathologic specimens, and concern 
that FTCs are rare and may be overdiagnosed is well established.45,66,85 However, the 
accuracy of SEER histology codes has been independently validated in a statewide 
registry, and SEER remains one of our strongest resources in the analysis of rare 
malignancies.97 The strengths of our study include the use of population-level data and 
the largest sample size to date, with long follow-up. 
Overall, our study shows that mFTC and mHCC are distinct clinicopathologic 
entities from mPTC which present more frequently with distant metastasis and are 
associated with compromised disease-specific survival. As a result, the possibility of 
mFHCC in patients with tumors ≤ 1cm in size and a cytologic diagnosis of follicular or 
Hurthle cell neoplasm should be strongly considered, and patients should undergo timely 
diagnostic lobectomy, which ultimately may be therapeutic as well. 
Pancreatic neuroendocrine tumors ≤ 2 cm 
 To our knowledge, this study is the first population-level analysis to exclusively 
characterize PNETs ≤ 2 cm in a surgical population. In addition to determining that the 
proportion of PNETs ≤ 2 cm in comparison to PNETs of all sizes has nearly doubled over 
the last 22 years, we found that nodal metastasis was not predictive of disease specific 
mortality, which was rather associated with high grade and black or Asian race. Also, we 
observed the rate of nodal metastasis in PNETs ≤ 2 cm to vary greatly between SEER 
versus institutional data. 
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 It is well documented that the incidence of PNETs has increased over the last 
three and a half decades. Lawrence et al. surveyed PNETs in the SEER database and 
found that their incidence rose from 1.7 per million in 1973-1977 to 4.3 per million in 
2003-2007.54 Vagefi et al. noted a trend towards smaller tumor size in incidentally 
diagnosed tumors in an institutional series of 168 PNETs, but the study was not 
sufficiently powered to establish statistical significance.98 Our study supports that PNET 
incidence continues to rise, and that the incidence of small PNETs is growing 
disproportionately in comparison to larger tumors on a population level. Furthermore, 
because this rate only reflects the incidence of PNETs deemed to be malignant, the 
disproportionality of the increase is likely underestimated. Overall, these findings 
highlight the necessity to more precisely characterize and define therapeutic strategies for 
this increasingly common population of patients. 
 With respect to clinical outcomes, no population-based studies have analyzed 
PNETs with a focus on size in a surgical population. Bilimoria et al. examined a surgical 
population utilizing the National Cancer Database (NCDB) and yielded similar results in 
comparison to SEER data with respect to age, gender, race, tumor location, nodal 
metastasis, and distant metastasis.58 Our study additionally highlights these 
characteristics in the context of tumor size. As expected, PNETs ≤ 2 cm were more likely 
to be lower grade, with lower rates of extrapancreatic extension, nodal metastasis, and 
distant metastasis compared to PNETs > 2 cm. Nevertheless, rates were still substantial, 
with 17.9% of PNETs ≤ 2 cm in the SEER database presenting with extrapancreatic 
extension, 27.3% with nodal metastasis, and 9.1% with distant metastasis. The 
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interpretation of this data, however, is complicated by the SEER database’s exclusion of 
PNETs thought to be benign, which results in the selection of a population of aggressive 
tumors that is not representative of PNETs ≤ 2 cm as a whole. One may correctly argue 
that the rate of nodal metastasis reported here is artificially high. However, while the 
exact frequency of nodal metastasis may be unclear, it appears that PNETs ≤ 2 cm, even 
microadenomas ≤ 0.5 cm, indeed have malignant potential.  
 Rates of nodal metastasis in PNETs ≤ 2 cm have been reported at 0%, 9%, and 
26% in various series.56,60,62 In our institutional series, the rate of nodal metastasis in 
PNETs ≤ 2 cm was 5.7%. Nodal metastasis has not been shown to be a predictor of 
survival in population level analyses of PNETs.58,59 However, this notion has recently 
been challenged. Parekh et al. argued that inadequate lymph node sampling precludes any 
conclusions about the prognostic power of nodal metastasis.99 In their single center series, 
no lymph node examination was documented in pathology reports in 37% of patients, and 
when lymph nodes were examined, only a median of five nodes were evaluated. While a 
median of ten nodes were examined in PNETs ≤ 2 cm in our institutional series, a median 
of six nodes were examined in PNETs ≤ 2 cm in the SEER database, confirming that 
lymph nodes may not be adequately sampled in the US. Therefore, while nodal 
metastasis was not a significant predictor of survival in our population-level cohort, this 
may be a result of inadequate lymph node sampling. 
 The two staging systems proposed for PNETs include those of the European 
Neuroendocrine Tumor Society (ENETS) and the American Joint committee on Cancer 
(AJCC). Although both have been validated in an American series of 123 patients, a 
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European series of 1,072 patients showed the ENETS system to be superior and nodal 
metastasis to be significantly associated with disease specific survival on univariate 
analysis.60,61 Our study emphasizes the prognostic significance of grade and race in 
tumors ≤ 2 cm. Black race been associated with lower rates of specialist consultation, 
chemotherapy, and resection in pancreatic adenocarcinoma.100 Similar factors may be 
affecting prognosis in black and Asian patients with small PNETs as well. 
 The limitations of this study include those inherent to the SEER database, such as 
coding errors, limited data for certain variables (for example, tumor grade), and lack of 
data on variables not collected by SEER (for example, mitotic rates, Ki67, incidental 
diagnosis, and recurrence). As discussed, the SEER database is restricted to tumors with 
an ICD-O-3 behavior code of 2 (in situ) or 3 (malignant), which selects for a population 
with artificially high rates of aggressive features. Because it is increasingly recognized 
that all PNETs > 0.5 cm have malignant potential, inclusion of such tumors in SEER that 
would have previously been designated as benign may have contributed to the observed 
increase in incidence. The strengths of this study include its relatively large sample size 
and use of population-level data. 
 Overall, our study confirms on a population-level that the incidence of small 
PNETs is increasing at a rapid rate, and that this group of tumors can display malignant 
behavior despite small tumor size. Furthermore, grade as well as Asian or black race were 
independent predictors of disease specific survival in tumors ≤ 2 cm. Resection versus 
observation, however, remains controversial. Additional studies that evaluate the full 
spectrum of benign and malignant disease, as well as prospective studies assessing the 
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necessary extent of lymphadenectomy will improve our understanding of the natural 
history of these small tumors and allow for optimization of surgical therapy. 
Conclusions 
Imaging has fundamentally changed the way patients with cancer present for 
surgical consultation. While the adoption of screening protocols in breast cancer has 
increased the diagnosis of localized cancers, it is uncertain whether the increasing 
incidences of thyroid cancers and PNETs are similarly due to the increased frequency of 
imaging in the era of modern medicine. Nevertheless, the increased utilization of 
ultrasound in the evaluation of thyroid pathology as well as frequent use of endoscopic 
ultrasound and axial imaging in evaluating diseases of the pancreas have likely played a 
role in the observed increases in incidence of small thyroid and endocrine pancreatic 
cancers. Furthermore, in all histologies studied, small cancers were capable of exhibiting 
aggressive behavior despite small tumor size, and additional studies that specifically 
examine the risks and benefits of surgical therapy in small tumors may clarify future 
surgical decision making 
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